Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 [Yahoo! Finance]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Yahoo! Finance
Rising anxiety, depression, and treatment-resistant conditions are stretching traditional therapies to their limits, forcing the industry to search for approaches that go beyond incremental relief. That search has brought psychedelic-assisted therapies back into focus, and this time backed by data, regulation, and serious capital. The space is now gaining legitimacy as clinical results and market demand begin to align. Within this evolving landscape, Mind Medicine (MNMD) has carved out a clear role. The company, also known as MindMed in short, is developing psychedelic-inspired treatments for brain health disorders, led by MM120, now advancing through late-stage trials for anxiety and depression. In 2025, MNMD stock reflected that progress, delivering strong gains as investors responded to clinical momentum and a maturing pipeline that extends into autism research. Super Micro Computer Stock Tumbles, But Investors are Piling into Its Call Options - Time to Buy SMCI? A $61 Billio
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) (NASDAQ:MNMD) is now covered by analysts at Jones Trading. They set a "buy" rating and a $61.00 price target on the stock.MarketBeat
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies [Seeking Alpha]Seeking Alpha
- Assessing Mind Medicine (MNMD)'s Valuation After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- MindMed Announces New Employee Inducement GrantBusiness Wire
MNMD
Earnings
- 11/6/25 - Miss
MNMD
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- MNMD's page on the SEC website